Zacks Investment Research downgraded Insys Therapeutics Inc (NASDAQ:INSY) to Sell in a report released today.
- Updated: September 15, 2016
Showing a price of $13.51, Insys Therapeutics Inc (NASDAQ:INSY) traded 0.37% lower on the day. The last stock price close is down 12.90% relative to the two hundred day average, compared to the S&P 500 Index which has decreased -0.01% over the same time period. INSY has been tracking to a 50-day moving average of $15.99 and 200-day moving average of $15.45. 708,907 shares of the stock traded, down from ann average volume of 811,878
Zacks Investment Research has downgraded Insys Therapeutics Inc(NASDAQ:INSY) to Sell in a report released Thursday September 15 2016.
Recent Performance Graph:
Also covering Insys Therapeutics Inc’s target price, a total of 5 equity analysts have released a research note on the stock. The one year target is $24.40 with one analyst rating the company a strong buy, three firms rating the company a buy, one analyst rating the stock a hold, 0 rating the company to underperform, and lastly 0 brokerages rating the company as sell.
With a market capitalization of $0.0, Insys Therapeutics Inc has a P/E of 20 with a 52 week low of $11.45 and a 52 week high of $37.19.
More About Insys Therapeutics Inc (NASDAQ:INSY)
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1, 200 and 1, 600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, and inhaled and intravenous formulations of dronabinol in preclinical studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.